https://scholars.lib.ntu.edu.tw/handle/123456789/523826
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Hsu J.-Y. | en_US |
dc.contributor.author | Perng R.-P. | en_US |
dc.contributor.author | Lu J.-Y. | en_US |
dc.contributor.author | Wu C.-P. | en_US |
dc.contributor.author | Huang M.-S. | en_US |
dc.contributor.author | KWEN-TAY LUH | en_US |
dc.contributor.author | PAN-CHYR YANG | en_US |
dc.creator | Hsu J.-Y.;Perng R.-P.;Lu J.-Y.;Wu C.-P.;Huang M.-S.;Luh K.-T.;Pan-Chyr Yang | - |
dc.date.accessioned | 2020-12-02T02:35:35Z | - |
dc.date.available | 2020-12-02T02:35:35Z | - |
dc.date.issued | 2006 | - |
dc.identifier.issn | 0929-6646 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-33749345328&doi=10.1016%2fS0929-6646%2809%2960198-4&partnerID=40&md5=40059e64910cc37dcdd730f51a19ab68 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/523826 | - |
dc.description.abstract | Background/Purpose: To compare the efficacy and safety of tiotropium and ipratropium in patients with chronic obstructive pulmonary disease (COPD) in Taiwan. Methods: This double-blind, randomized, placebo-controlled, parallel group study was conducted at six hospitals in Taiwan. COPD patients aged ? 40 years, with a forced expiratory volume in 1 second (FEV1) ? 65% of predicted and FEV1/forced vital capacity (FVC) ? 70% were enrolled. After a 2-week screening/baseline period, 132 patients were randomized to receive 4 weeks of treatment with either tiotropium 18 μg once daily from a dry powder inhaler (HandiHaler?) or two puffs of ipratropium. 20 μg four times daily from a metered dose inhaler. The primary outcome was the change in trough FEV1 from baseline to week 4. The secondary outcome measures were trough FVC response, FEV1 and FVC responses at 2 hours postinhalation. Results: After 4 weeks, trough FEV1 had increased by 61.7 ± 25.3 mL for tiotropium but decreased by 16.4 ± 27.9 mL for ipratropium. The difference between groups was significant (p < 0.05; 95% CI, 10-146.1). The trough FVC also increased by 137.2 ± 49.3 mL for tiotropium but was decreased by 84.5 ± 54.5 mL for ipratropium (p < 0.001; 95% CI, 89.0-354.3). No major drug-related adverse events associated with tiotropium and ipratropium were observed. Conclusion: Tiotropium 18 μg once daily using HandiHaler? was significantly more effective than ipratropium 40 μg four times daily in improving trough FEV1 and FVC over a 4-week period. The safety profiles of both drugs are comparable. ? 2006 Elsevier & Formosan Medical Association. | - |
dc.publisher | Scientific Communications International Ltd | - |
dc.relation.ispartof | Journal of the Formosan Medical Association | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | fenoterol; fenoterol plus ipratropium bromide; ipratropium bromide; ipratropium bromide plus salbutamol sulfate; placebo; tiotropium bromide; adult; aged; article; bronchodilating activity; chronic obstructive lung disease; clinical trial; comparative study; controlled clinical trial; controlled study; disease exacerbation; double blind procedure; drug efficacy; drug safety; forced expiratory volume; heart atrium fibrillation; human; lung disease; major clinical study; mass screening; metered dose inhaler; multicenter study; parallel design; powder inhaler; randomized controlled trial; side effect; statistical significance; Taiwan; treatment outcome; urinary frequency | - |
dc.title | Double-blind randomized parallel group study comparing the efficacy and safety of tiotropium and ipratropium in the treatment of COPD patients in Taiwan | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1016/S0929-6646(09)60198-4 | - |
dc.identifier.pmid | 16959618 | - |
dc.identifier.scopus | 2-s2.0-33749345328 | - |
dc.relation.pages | 708-714 | - |
dc.relation.journalvolume | 105 | - |
dc.relation.journalissue | 9 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
crisitem.author.dept | Laboratory Medicine | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Clinical Pharmacy | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Biomedical Electronics and Bioinformatics | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.orcid | 0000-0001-6330-6048 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Electrical Engineering and Computer Science | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。